FDA introduces ‘green list’ for GLP-1 drug ingredient imports

Lenora S. Newsome, President
Lenora S. Newsome, President | National Association of Boards of Pharmacy

The Food and Drug Administration (FDA) has created a "green list" import alert to prevent unverified glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredients (APIs) from entering the United States. The initiative is designed to ensure that only GLP-1 APIs produced by facilities meeting FDA standards are allowed into the U.S. supply chain.

According to the FDA, this measure aims to reduce the risk of unsafe or substandard GLP-1 drugs reaching consumers. The agency stated it will continue working with state regulators and monitor the market for potential threats related to these drugs.

"The green list will record the GLP-1 APIs produced by facilities that comply with FDA’s standards. FDA notes that it will continue to monitor the market and work with state regulators to prevent unsafe GLP-1 drugs from entering the US."

This action reflects ongoing efforts by federal authorities to safeguard public health by tightening controls on pharmaceutical imports.